Abstract: Provided herein are apparatuses, systems and methods for non-invasively assessing synaptic dysfunction in a patient with Alzheimer's Disease. Transcranial magnetic stimulation (TMS) is applied to at least one brain region of the patient. A plurality of TMS evoked potentials generated in response to the TMS applied to the at least one brain region of the patient is recorded with a plurality of electroencephalography (EEG) electrodes. At least one characteristic of the plurality of TMS evoked potentials is analyzed to assess synaptic dysfunction in the patient. An indication of the synaptic dysfunction assessment of the patient is output.

Abstract: Disclosed herein are devices, systems, and methods for ameliorating or treating or preventing Alzheimer's Disease and related dementias. Methods may include using individual patients' data to identify the optimal treatment target(s) as well as the stimulation intensity, frequency, or waveform, or any combination thereof, for transcranial electromagnetic induction delivered via a device as in the case of Transcranial Magnetic Stimulation. Systems and methods include a platform or infrastructure for treatment delivery and data processing. In some embodiments, methods are applied to restore cognitive function, ameliorate clinical symptoms, modify altered mechanisms of plasticity, modulate cortical excitability and reactivity, or induce changes in local brain metabolism.

Abstract: Disclosed herein are devices, systems, and methods for ameliorating or treating or preventing Alzheimer's Disease and related dementias. Methods may include using individual patients' data to identify the optimal treatment target(s) as well as the stimulation intensity, frequency, or waveform, or any combination thereof, for transcranial electromagnetic induction delivered via a device as in the case of Transcranial Magnetic Stimulation. Systems and methods include a platform or infrastructure for treatment delivery and data processing. In some embodiments, methods are applied to restore cognitive function, ameliorate clinical symptoms, modify altered mechanisms of plasticity, modulate cortical excitability and reactivity, or induce changes in local brain metabolism.

Abstract: Disclosed herein are devices, systems, and methods for ameliorating or treating or preventing Alzheimer's Disease and related dementias. Methods may include using individual patients' data to identify the optimal treatment target(s) as well as the stimulation intensity, frequency, or waveform, or any combination thereof, for transcranial electromagnetic induction delivered via a device as in the case of Transcranial Magnetic Stimulation. Systems and methods include a platform or infrastructure for treatment delivery and data processing. In some embodiments, methods are applied to restore cognitive function, ameliorate clinical symptoms, modify altered mechanisms of plasticity, modulate cortical excitability and reactivity, or induce changes in local brain metabolism.

Abstract: This disclosure relates to the pharmacological treatment of apathy and loss of executive function in treatment of neurodegenerative diseases by administration of a combination drug formulation including rotigotine and an acetylcholinesterase inhibitor.